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Proliferation by Blocking Lipid
Synthesis Activation
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Departamento de Química Biológica Ranwel Caputto, Facultad de Ciencias Químicas, Centro de Investigaciones en Química
Biológica de Córdoba (CIQUIBIC-CONICET), Universidad Nacional de Córdoba, Córdoba, Argentina
Tumor cells require high rates of lipid synthesis to support membrane biogenesis for
their exacerbated growth. The only two proteins known that activate phospholipid
synthesis are Fra-1 and c-Fos, two members of the AP-1 family of transcription factors.
These proteins that are overexpressed in human breast malignant tumors increase
the rate of phospholipid synthesis at the endoplasmic reticulum through a mechanism
independent of their nuclear function. The aim of this study was to inhibit breast tumor
cell proliferation by modulating c-Fos and Fra-1 and regulate membrane biogenesis
by controlling lipid synthesis rates. The molecular mechanism by which Fra-1 and
c-Fos activate phospholipid synthesis was examined. Both proteins physically associate
with the rate limiting enzyme CDP-DAG synthase through their N-terminus domain
and activate it through their basic domain; neither protein associates to or activates
the enzyme phosphatidylinositol synthase as determined through in vitro enzymatic
reactions and FRET experiments. The N-terminus domain of both proteins act as negative
dominant peptides that physically associate with CDP-DAG synthase but do not activate
it. Proliferation of MDA-MB231 and 4T1 cells was impaired in vitro after inducing them
to proliferate in the presence of the negative dominant peptides derived from Fra-1 and
c-Fos. When tumors generated in Balb/c mice with the breast tumor cell line 4T1 were
treated with these negative dominant peptides, a significant reduction in tumor growth
was observed. Consequently, these Fra-1 and c-Fos negative dominant peptides can be
exploited as a new therapeutic strategy to impair breast tumor cell proliferation.
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INTRODUCTION
Breast cancer is the most frequent cancer among women (25% of all cancers) and the main cause
of cancer deaths in less developed countries (1). According to the World Health Organization, its
incidence is increasing worldwide. Although prevention and early detection significantly reduce
death risk, they do not eliminate most breast cancers that develop in low- and middle-income
countries where these are diagnosed at late stages and generally result in patient death. Breast cancer
is the fifth cause of cancer deaths after lung (1.6 million deaths), liver (745,000 deaths), stomach
(723,000 deaths), and colorectal (694,000 deaths) cancers (2). So, development of new therapeutic
strategies targeted to inhibit breast tumor cell proliferation in established tumors is essential.
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Fra-1 and c-Fos are two well-known oncogenes, members
of the AP-1 family of transcription factors (3, 4). Their
nuclear activity and overexpression in diverse tumors has been
widely reported (5). Fra-1 is overexpressed in breast, lung,
colon, esophagus, bladder, thyroid and hepatocellular tumors,
among others (5–13). Moreover, Fra-1 has been implicated in
cervical cancer stem cell radio-resistance (14), in the malignant
progression of esophageal squamous cell carcinoma through
MAPK/MEK/ERK/FRA-1 pathway activation (15), in epithelial-
mesenchymal transition regulation of colorectal cancer cells (16,
17), in cancer stem cell formation from non-stem cells in a
PKCα-dependent activation of Fra-1 (18), and in the inhibition
of p53-dependent apoptosis in lung cancer (19). However,
despite having been studied for almost 30 years, the cellular
consequences of c-Fos and Fra-1 expression upon mitogen
stimulation have not been completely elucidated.
In breast tumors, the transcription factors Fra-1 and c-Fos are
also expressed in the cytoplasm where they activate phospholipid
synthesis (20). Phospholipids are the quantitatively most
important components of cell membranes thus making their
production essential to sustain cell proliferation, differentiation
and growth. Tumor cells are characterized by their exacerbated
growth and so, demand high rates of phospholipid synthesis
to support increased membrane biogenesis. Fra-1 and c-Fos
show a similar capacity to activate phospholipid synthesis
in proliferating breast tumor cells in culture (MDA-MB231
and MCF-7 cells) and in human breast tumor tissues. In
more than 200 malignant human breast tumors examined
(Invasive ductal carcinoma, Medullary carcinoma, Phyllodes
sarcoma, Mucinous carcinoma, lobular carcinoma in situ and
squamous cell carcinoma) 95% of both proteins were significantly
overexpressed and 100% had either Fra-1 or c-Fos overexpressed
contrasting with their undetectable levels in normal tissue.
Fra-1 was found mainly in the cytoplasm: 69% of tumor
samples showed only cytoplasmic Fra-1, while the remaining
31% contained both nuclear and cytoplasmic Fra-1. c-Fos was
also preferentially in the cytoplasm of the tumor samples: 100%
showed cytoplasmic c-Fos and 63% also contained nuclear c-
Fos. In all cases, Fra-1 and c-Fos localized with the Endoplasmic
Reticulum (ER) marker calnexin where they both participate
in the bulk phospholipid synthesis. Silencing Fra-1 and c-Fos
simultaneously and, more importantly, blocking the cytoplasmic
activity of these proteins with specific antibodies significantly
inhibits lipid synthesis activation and cell proliferation in MDA-
MB231 cells (20). Based on these results, cytoplasmic c-Fos
and Fra-1 deserve to be considered as potential targets to
control proliferation of breast cancer cells. To seek a therapeutic
application of these results, we determined the molecular
mechanism by which these proteins activate phospholipid
synthesis. For c-Fos to promote activation, it must associate with
enzymes of the lipid synthesis pathway in the ER, through its N-
terminal domain (aa 1–138) and increases their catalytic activity
through its basic domain (aa 139–159) (21). c-Fos association to
the ER is regulated by the phosphorylation status of its tyrosine-
residues #10 and #30 (22).
c-Fos activates several and the same enzymes in different
cell types. Specifically, c-Fos activates 1-acylglycerol-3-phosphate
acyltransferase, CDP-diacylglycerol synthase (CDS) the rate-
limiting enzyme of the phosphoinositide synthesis pathway,
phosphatidylinositol 4-kinase II α (PI4KIIα) and Lipin1β which
drives phosphatidic acid into the Kennedy pathway. However, c-
Fos does not modify the activity of phosphatidylserine synthases
1 and 2, phosphatidylinositol synthase (PIS) or PI4KIIβ (21,
23, 24). A similar effect is observed for glycosphingolipid
synthesis, in which c-Fos activates glucosylceramide synthase
but does not affect glucosylceramide galactosyltransferase 1 or
lactosylceramide sialyltransferase 1 (25). Fra-1 also activates the
overall synthesis of phospholipids and has been shown to activate
Lipin 1β (20, 26). However, the mechanism by which Fra-1
activates phospholipid synthesis still remains unexplored.
Herein, we examine the mechanism by which Fra-1 activates
phospholipid synthesis in a breast tumor cell model. Two
enzymes were examined; one that was previously shown to be
activated by c-Fos (CDS) and one whose activity is not modified
by c-Fos (PIS). We observed that Fra-1 associates to CDS1
and activates total CDS, whereas it neither associates to nor
activates PIS.
Results shown herein indicate that Fra-1 and c-Fos can be
the foundation for a novel therapeutic strategy to inhibit breast
tumor growth by impairing membrane biogenesis.
MATERIALS AND METHODS
Cell Culture
MDA-MB231 and 4T1 cells from ATCC were cultured as
indicated by the supplier. Mycoplasma control was regularly
performed. Cultured cell quiescence was achieved after culturing
48 h using DMEM without FBS and phenol red. Cells were
induced to re-enter growth by adding 20% FBS.
Proliferation Assay
Transfections were performed following the manufacturer’s
instructions in 24 multi-well plates using Lipofectamine 2000
(Invitrogen) plus 400 ng of pTQ2-Fra-1-NA or pTQ2-c-Fos-NA,
or a mixture of 200 ng of each. Control cells received 400 ng
of the pTQ2 vector. Twenty-four hours after transfection, cells
were cultured in serum-free media for 48 h to achieve quiescence
(0 h), then 20% FBS was added to the culture medium (mitotic
stimulus) and cells cultured for an additional 30 h. Turquoise
fluorescence was used to determine the number of transfected
cells; total cell number by propidium iodide staining and double
blind cell counting in each condition was performed in at least 20
fields per experiment. By subtracting the number of transfected
cells from total cells, the number of non-transfected cells was
determined at 0 h and at 30 h. Cell proliferation was calculated
as the ratio between the number of cells at 30 h/0 h.
Expression and Purification of
Recombinant Proteins
Recombinant proteins were expressed as His-tagged
recombinant proteins in the BL21 strain of Escherichia coli
and purified as described previously (27, 28) by nickel affinity
chromatography. Cells were re-suspended in lysis buffer
containing 6M urea for wild type proteins or without 6M urea
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for deletion mutants and lysed using the Avestin Emulsiflex
C3. Cell homogenates were run through a HisTrap HF column
(GE Healthcare Life Sciences), washed thoroughly and proteins
purified using an Äkta Purifier 10 (GE Healthcare Life Sciences).
Elution buffer (0.5M NaCl, 20mM Tris-HCl pH 8, 500mM
imidazole) with Urea (6M) was used for c-Fos and Fra-1, and
without urea for Fra-1 deletion mutants and c-Fos-NA. Final
imidazole concentration in the eluted proteins was 171 mM.
Enzyme Activity Determinations
Reactions performed in a final volume of 80 µL contained, 100
µg of quiescent MDA-MB231 cell homogenate protein in 50mM
Tris-HCl, pH 8 (enzyme source). For enzyme activity assays in
animal excised tumors, homogenates were prepared in water
containing protease inhibitors using a Potter-Elvehjem Tissue
Grinder, prior to sonication. Total CDS activity was assayed as
described by Lykidis et al. (29) with or without the recombinant
c-Fos, Fra-1 or its deletion mutants Fra-1-NA, Fra-1-NB, Fra-1-
BC, as stated in each case, suspended in 3 µL of elution buffer or
an equal volume of elution buffer for control reactions.
Total PIS activity reactions were as described by Lykidis et al.
(29) in the presence of c-Fos or Fra-1 suspended in 3 µL of
elution buffer or with elution buffer for control reactions.
Colocalization Analysis
MDA-MB231 cells were co-transfected with pEGFP-Fra-1 or
pEGFP-c-Fos and both NA deletion mutants fused to the HA
tag or the control with the empty vector. Immunofluorescence
was performed using anti-HA (mouse Sigma #H9658 1:100)
and anti-calreticulin (rabbit Thermo Scientific #PA3-900 1:800),
secondary antibodies: anti-mouse 546 and anti-rabbit 643
(1:600). A spectral Olympus (Center Valley, PA) FV 1200
confocal laser scanning microscope with a plan apochromatic
60x (SC), numerical aperture 1.4, oil immersion objective lens
zoomed digitally 5x was used. Mander’s colocalization coefficient
M1 (proportion of Fra-1 or c-Fos present in the ER) with
threshold was used to quantify colocalization using the Fiji
software and the Jacop plugin.
FRET Analyses
FRET experiments were performed as described previously (21).
Cells transfected with GFP derivatives-coupled enzymes and
proteins/peptides as indicated were arrested for 48 h. CDS1
and PIS (pSYFP2-N1) and pTQ2-c-Fos were previously used
(21). Wild type Fra-1 and truncated mutants of Fra-1 were
in pTurquoise2-N1. Synthesis of endogenous c-Fos and Fra-
1 was impaired using 50µg/mL of cycloheximide 1 h prior to
inducing cells to re-enter growth with FBS. Fifteen minutes
later, cells were fixed with 4% paraformaldehyde for 10min at
room temperature. Mounted Coverslips were visualized using
an Olympus FV300 confocal laser scanning microscope with a
plan apochromatic 63x, numerical aperture 1.4, oil immersion
objective lens zoomed digitally 2x. FRET determinations were
by measuring sensitized emission (30, 31). Images analyzed with
Fiji (NIH, USA) were pseudo-colored to illustrate the calculated
efficiencies distribution in cells.
Treatment of Breast Tumors in vivo
This study was carried out in accordance with the
recommendations of the ethics committee of experimental
protocols for the use of animals (Facultad de Ciencias Químicas,
Universidad Nacional de Córdoba). The protocol was approved
by the ethics committee of experimental protocols for the use of
animals (Facultad de Ciencias Químicas, Universidad Nacional
de Córdoba. Resolution N◦ 2102). The mouse-4T1 breast tumor
model was used as described in Pulaski et al. (32). Ten days after
inoculation, animals received an intra-tumor injection at 3-days
intervals of either Fra-1-NA + c-Fos-NA-containing liposomes
(treated) or empty liposomes (controls). Liposomes were
prepared by the lipid film hydration method (33, 34). Briefly,
diphosphatidylcholine, diphosphatidylserine, and cholesterol
(Avanti Polar Lipids 850355P, 840037P, 700000P) (70:10:20 ratio)
were dissolved in chloroform (5 mg/mL) and evaporated under
nitrogen. Hydration was performed by addition of the peptide
solution or vehicle (peptide elution buffer) followed by five
cycles of incubation at 55 ◦C and vortexing. Liposome size was
determined by light scattering. A total amount of 22.5 nmol of
peptides/mouse in 5 injections delivered 3 times a week was used
in low dose experiments. Each injection contained 2.5 nmol of
Fra-1-NA (30 µg) plus 2 nmol of c-Fos-NA (30 µg) contained in
liposomes re-suspended in 50µL of peptide elution buffer for the
first 2 injections and in 100 µL for the last 3 injections. Empty
liposomes (controls) were re-suspended in elution buffer as for
the treated animals. For high dose experiments, total peptide
administered was 45 nmol/mouse in 5 injections delivered 3
times a week, each containing 5 nmol of Fra-1-NA (60 µg) plus
4 nmol of c-Fos-NA (60 µg) re-suspended in 50 µL of elution
buffer for the first 2 injections and in 100 µL for the last 3
injections. Injection volume was varied due to the variation of
the tumor volume.
When each mouse harbored 2 tumors, animals received a
2 × 105 4T1 cell inoculation into each fat pad and upon
tumor generation, one tumor was subjected to the high dose
treatment protocol described above whereas the other tumor
of the same animal was treated as described for the control
group. In all cases, tumors (length, width) were measured using
a caliper. For western blot experiments, tumors were excised and
frozen (−80◦C).
Western Blotting
Using sonication, tumor tissues were processed in ice-cold RIPA
buffer (150mM NaCl, 1% Triton, 50mM Tris-HCl pH 6.8,
0.5mM EDTA, SDS 0.01%) plus protease inhibitor (Roche)
and centrifuged for 10min at 12,000 g. Protein extracts were
separated on a 12% SDS-PAGE and transferred to nitrocellulose
membrane (Pall Corporation). After blocking with 5% non-fat
milk in 1X PBS—0.05% Tween-20, membranes were incubated
with primary antibodies (mouse monoclonal anti-α-tubulin,
Abcam ab7291; 1:5,000 and anti-PCNA, Santa Cruz PC10; 1:250)
overnight at 4◦C. After washing, blots were incubated with
donkey anti-mouse IRDye IgG secondary antibody (LI-COR
Bioscience, Lincoln, NE, USA; 1:25,000) at room temperature for
1 h. Immuno-detection was performed using ODYSSEY Infrared
Imaging System (LI-COR Bioscience).
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RESULTS
Fra-1 and c-Fos Activate CDS but Not PIS
Previous results from human breast tumors show that 100% of
these overexpress either Fra-1 or c-Fos or both oncoproteins;
furthermore, non-fixed samples showed activated phospholipid
synthesis with respect to control human breast tissue (20). To
evaluate the potential therapeutic use of peptides derived from
these proteins, we determined if these two proteins share a
common mechanism to activate the synthesis of phospholipids,
by evaluating their capacity to regulate two enzymes of the
pathway of phospholipid synthesis.
To assess the capacity of Fra-1 to activate the enzymes
CDS and PIS in vitro, total homogenate (TH) from quiescent
MDA-MB231 cells was used as enzyme source. Total CDS
activity is linear up to 60min of incubation (Figure 1A) whereas
PIS activity is linear up to 15min of incubation (Figure 1B).
At linearity, CDS activity increased in the presence of 0.5
ng of recombinant Fra-1/µg of TH in comparison with the
control. By contrast, PIS activity was not significantly modified
by the addition of Fra-1 to the assay as compared to the
control (Figure 1B). For PIS, increasing concentrations of
recombinant Fra-1 were also tested with no changes under any
of the experimental conditions evaluated [0–3 ng of Fra-1/µg
TH (Supplementary Figure 1)]. Essentially the same results
were found when recombinant c-Fos (0.5 ng/µg of TH) was
assayed (Figures 1A,B).
The NB Deletion Mutant of Fra-1
Activates CDS
To determine which domains of Fra-1 are involved in CDS
activation, CDS was assayed in the presence of the deletion
mutants of Fra-1 schematized in Figure 1C: Fra-1-NA (aa 1–
107), Fra-1-NB (aa 1–127) and Fra-1-BC (aa 108–271). Fra-
1-NB activates CDS to comparable levels as full-length Fra-1
whereas no activation was observed with Fra-1-NA or Fra-1-BC
(Figure 1D). Note that Fra-1-NB is the only mutant assayed that
contains both the NA and the BD domains of Fra-1.
Fra-1 Physically Associates With CDS1 but
Not With PIS
FRET experiments were performed to evaluate if Fra-1 physically
interacts with CDS1 or PIS. MDA-MB231 cells were co-
transfected with constructs encoding full length Fra-1 fused to
a donor FRET-pair (pTQ2) and each enzyme assayed, CDS1 or
PIS, fused to an acceptor FRET-pair (pSYFP). Results show that
Fra-1 associates with CDS1 (Figure 2A, row 2) but not with PIS
FIGURE 1 | Fra-1 activates CDS through its NB domain. (A,B) Total homogenate (TH) from quiescent MDA-MB231 cells was used as enzyme source to evaluate total
CDS and PIS activity in the presence of Fra-1 (0.5 ng of recombinant Fra-1 per ug of TH; short dashed line) or c-Fos (0.5 ng of recombinant c-Fos per ug of TH; long
dashed line) in comparison with the controls that contained only the vehicle used to re-suspend Fra-1 or c-Fos (continuous line). Both c-Fos and Fra-1 significantly
activate CDS (A) at the incubation times examined whereas neither of them significantly modified PIS activity (B). (C) Schematic representation of the deletion mutants
of Fra-1. The numbers on the top of the scheme indicate the amino acid position. Fra-1-NA: N-terminus (aa 1–107), Fra-1-NB: N-terminus plus basic domain (aa
1–127), Fra-1-BC: basic domain plus the C-terminus (aa 108–271). (D) CDS activity was evaluated in the presence of recombinant Fra-1 or of its deletion mutants.
Only Fra-1-NB activates the enzyme to similar levels as those obtained with the full-length version, whereas Fra-1-NA that lacks the BD or Fra-1-BC that lacks the NA
do not retain this activating capacity. *p < 0.05; **p < 0.01; ***p < 0.001 (Two-way ANOVA in A,B and 1 way ANOVA in D). Results are the mean CDS activity ± SEM
of three independent experiments performed in triplicate.
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FIGURE 2 | Fra-1 and c-Fos physically associate with CDS1 but not with PIS. (A) MDA-MB231 cells were co-transfected to express pTQ2 and pSYFP-CDS1 (first
row) as a negative control, pTQ2-Fra-1 and pSYFP-CDS1 (second row), pTQ2-Fra-1 and pSYFP-PIS (third row), pTQ2-c-Fos and pSYFP-CDS1 (fourth row) or
pTQ2-c-Fos and pSYFP-PIS (last row), and examined by confocal microscopy; for FRET efficiency quantification, the sensitized emission method was applied. The
first column shows tagged Fra-1 or c-Fos expression, the second, the expression of the tagged enzyme and the third column shows FRET efficiency; the scale bar on
the bottom row shows an increasing FRET efficiency scale from violet (no FRET) to white. (B) FRET efficiency quantification is depicted as boxplot graphs representing
the medians (central horizontal bars), the 25–75th percentile interquartile range (box limits), and the lowest and highest values (whiskers). ***p < 0.001 (Kruskal-Wallis
test, Dunn’s post-test). One representative experiment of three performed that gave essentially the same results, is shown.
(Figure 2A, row 3). Cells co-transfected with the pTQ2 vector
and CDS1 fused to pSYFP show negative FRET values (negative
control) (Figure 2A, row 1). Positive FRET values were also
found with tagged c-Fos and CDS1 but not with tagged c-Fos and
PIS (Figure 2A, rows 4 and 5). Quantification shows statistically
significant FRET efficiencies with CDS1 when compared to
negative controls whereas neither Fra-1 nor c-Fos shows positive
FRET efficiencies when assayed with PIS (Figure 2B). These
results evidence that Fra-1 and c-Fos physically associate with the
enzyme (s) they activate, like CDS1, but not with those they do
not activate, such as PIS.
Fra-1 Associates With CDS1 Through Its
N-terminus Domain
To determine which domain (s) of Fra-1 is/are involved
in physical association with CDS1, we performed FRET
experiments with the three Fra-1 deletion mutants Fra-1-NA,
Fra-1-NB and Fra-1-BC (Figure 1C). MDA-MB231 cells were
co-transfected with constructs codifying for Fra-1 or its deletion
mutants fused to pTQ2 and CDS1 fused to pSYFP. The mutants
Fra-1-NA and Fra-1-NB show positive FRET efficiencies with
CDS1, similar to that observed with full-length Fra-1 and
statistically different from the negative control (pTQ2 and
CDS1 fused to SYFP) (p < 0.001 and p < 0.01, respectively)
(Figures 3A,B). By contrast, Fra-1-BC that lacks the N-terminus
domain, does not associate with CDS1 showing similar FRET
efficiency to that of the negative control (p > 0.05) (Figure 3A,
row 5 and Figure 3B). These experiments evidence that Fra-1
associates to CDS1 through its N-terminus domain and that the
BD domain is not essential for this association.
Colocalization of Fra-1 and c-Fos With the
ER Marker Calreticulin Decreases in the
Presence of Fra-1-NA and c-Fos-NA
Previous reports indicate that Fra-1 and c-Fos colocalize with
the ER marker calnexin in human breast tumor samples, and in
MDA-MB231 and MCF7 breast tumor cell lines (20). Herein, we
quantified the colocalization between Fra-1 or c-Fos and the ER
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FIGURE 3 | The N-terminus domain of Fra-1 physically associates with CDS1. (A) MDA-MB231 cells were co-transfected to express the negative control pTQ2 and
pSYFP-CDS1 (first row), pTQ2-Fra-1 and pSYFP-CDS1 (second row), pTQ2-Fra-1-NA and pSYFP-CDS1 (third row), pTQ2-Fra-1-NB and pSYFP-CDS1 (fourth row)
or pTQ2-Fra-1-BC and pSYFP-CDS1 (last row), and were examined by confocal microscopy. FRET quantification was performed by the sensitized emission method.
The first column shows the expression of tagged Fra-1 or of its deletion mutants, the second of the tagged enzyme and the third column shows FRET efficiency. The
scale bar on the bottom row of the right column shows an increasing FRET efficiency scale from violet (negative) to white (maximum). (B) FRET efficiency quantification
depicted as boxplot graphs representing the medians (central horizontal bars), the 25–75th percentile interquartile range (box limits), and the lowest and highest
values (whiskers). **p < 0.01; ***p < 0.001 (Kruskal-Wallis test, Dunn’s post-test). One representative experiment of three performed, which gave essentially the same
results, is shown.
marker calreticulin in the absence or in the presence of Fra-1-
NA plus c-Fos-NA deletion mutants by determining Mander’s
colocalization coefficient M1. For this, MDA-MB231 cells were
co-transfected with pEGFP-Fra-1 or pEGFP-c-Fos and the N-
terminal deletion mutants fused to the HA tag, that is Fra-1-
NA-HA and c-Fos-NA-HA or the control with the HA plasmid.
GFP signal was directly detected whereas HA and calreticulin
were detected by indirect immunofluorescence using specific
antibodies. The results in Supplementary Figure 2 show that
Mander’s colocalization coefficient M1 that is the proportion of
Fra-1 or c-Fos localized in the ER compartment, decreases in the
presence of Fra-1-NA and c-Fos-NA.
The N-terminus Domain of Both Fra-1 and
c-Fos Inhibit MDA-MB231 and 4T1 Cell
Proliferation
Since Fra-1 and c-Fos physically associate with CDS1 through
their N-terminus domain and activate it through their BD
domain, and both are overexpressed in breast tumor tissues in
comparison with their undetectable levels in normal tissue (20),
we hypothesized that the NA domains of both proteins, could
function as negative dominants of the cytoplasmic activity of c-
Fos and Fra-1 by associating with the enzymes that the full-length
proteins activate, but without activating them. So, it is expected
that the presence of these deletion mutants, will promote
a decrease in phospholipid biosynthesis rates and therefore
will decrease or inhibit membrane biogenesis-dependent cell
proliferation. To test this hypothesis, we transiently transfected
MDA-MB231 cells to overexpress either Fra-1-NA, c-Fos-NA,
or both, tagged with a TQ2 fluorescent protein. At 48 h after
transfection, quiescent cells were induced to re-enter growth and
proliferation assessed as described under materials and methods.
Overexpression of either of the NA deletion mutants alone
or, both mutants together, significantly decrease the number
of cells at 30 h after the mitotic stimulus as compared to
controls (Figure 4A). Similar experiments were performed using
the 4T1 mouse mammary carcinoma cell line showing similar
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FIGURE 4 | Fra-1-NA and c-Fos-NA inhibit MDA-MB231 and 4T1 cell proliferation. MDA-MB231 (A) or 4T1 cells (B) were transfected to express pTQ2-Fra-1-NA, or
pTQ2-c-Fos-NA, or pTQ2-c-Fos-NA + pTQ2-Fra-1-NA. The number of cells expressing the turquoise fluorescent protein (T: dark gray bars) and the number of
non-transfected (NT: light gray bars) cells (propidium iodide stained cells—turquoise cells) present in the same well were counted at 0 h (arrested cells: t0) and 30 h
after a mitotic stimulus (20% fetal bovine serum: t30). The ratio between the number of T or NT cells at t30 and t0 is shown and the mean indicated in each bar.
Results are expressed as mean ± SEM (n = 3). *p < 0.05; **p < 0.01 ***p < 0.001 (ANOVA, Bonferroni post-test). (C) Representative images of 4T1 cells at t0
(arrested cells) and t30 (after 30 h of a mitotic stimulus) of the control condition transfected with the pTQ2 vector (upper panel) and the condition transfected with
pTQ2-c-Fos-NA + pTQ2-Fra-1-NA (lower panel). Total cells stained with PI (left column), and transfected cells (middle column) are shown in black and white and the
colored merge in right column. PI: propidium iodide (red), TQ2 (cyan). Original Magnification 400×.
results (Figures 4B,C). The presence of the pTQ2 vector did
not significantly alter 4T1 (Figures 4B,C) or MDA-MB231 cell
proliferation as compared to non-transfected cells.
The N-terminus Domains of Fra-1 and
c-Fos Inhibit Breast Tumor Growth in vivo
in a Balb/c Mice Tumor Model
As both Fra-1-NA and c-Fos-NA interfere with the proliferation
of breast tumor cells in culture, we verified if these deletion
mutants were capable of interfering with breast tumor growth
in vivo. For this, the 4T1 breast tumor model was used (32).
As indicated under Materials and Methods, two protocols were
used for treatment, one with a 60 µg dose of 30 µg each of
Fra-1-NA plus c-Fos-NA per injection (4.5 nmol per injection)
and the other with a 120 µg dose of 60 µg of each peptide per
injection (9 nmol per injection). After 15 days of treatment with
both doses of Fra-1-NA- plus c-Fos-NA-containing liposomes,
a significant reduction in tumor volume and tumor growth
rate was found as compared to control tumors (Figures 5A,C:
low dose; Figures 5B,D: high dose). However, by day 15 of
treatment (day 25 post inoculation), control tumors reached a
tumor volume ∼50% larger than those treated with the lowest
dose of both N-terminus deletion mutants whereas they almost
doubled the size of those treated with the higher dose. No
significant differences were observed in the body weight between
groups (Figures 5E,F).
To evaluate the proliferating status of the treated and control
tumors, once tumors were excised from the animals of the high
dose experiment, protein extracts were prepared from the tumors
and proliferating cell nuclear antigen (PCNA) protein levels
determined by western blot. Fra-1-NA plus c-Fos-NA-treated
tumors showed a significant decrease in PCNA protein levels in
comparison to the controls (Figure 6). The lowest PCNA levels
in individual samples were found in the tumors with the lowest
growth rate (data not shown), indicating a good correlation
between the amount of PCNA found and the tumor growth rate
calculated for each tumor.
To evaluate if the Fra-1-NA plus c-Fos-NA-treatment was
triggering a systemic effect on tumor growth, assays were
performed inoculating 4T1 cells into both flanks of each mouse
and 10 days later, one of the two tumors generated was treated
with the high dose protocol whereas the other was treated
with vehicle. Consistently, tumors treated with the deletion
mutants grew to a significantly smaller tumor volume and
evidenced a decreased tumor growth rate when compared with
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FIGURE 5 | Fra-1-NA plus c-Fos-NA inhibit breast tumor growth. Mice bearing one tumor received an intratumoral injection of liposomes containing Fra1-NA plus
c-Fos-NA. Peptide administered: 5 injections containing 4.5 nmol per injection (dashed line) or vehicle (continuous line) (A,C,E) or 9 nmol per injection (B,D,F) delivered
three times a week for 15 days. In (A,C,E), control group: n = 6; treated group: n = 8; in (B,D,F), control group: n = 4; treated group: n = 6. (A,B) Tumor volumes
were measured at 3-day intervals during the treatment period. Results are expressed as the percent volume taking the volume of the tumor at 10 days of inoculation
as 100%. ***p < 0.001 (Two-way ANOVA, Bonferroni post-test). (C,D) Tumor growth rates were calculated for each group at the end of the treatment as the slope of
the curve obtained by plotting the log10 of the tumor volume in function of the days of treatment. Horizontal bars represent mean (C) or median (D) values according
to the distribution of the data (parametric and non-parametric ANOVA, respectively) *p < 0.05; **p < 0.01. (E,F) Body weight of animals during the treatment period.
the contralateral control tumor (Figures 7A,B). Once excised
from the animals, paired control and treated tumors from two
mice were used to evaluate total CDS activity. In both cases,
CDS activity measured in TH of the vehicle-treated tumor was
significantly higher than that obtained in TH of the paired Fra-
1-NA plus c-Fos-NA-treated tumor from the same mouse (light
gray bars in Figures 7C,D). Furthermore, when these tumor
samples were stripped of associated proteins with 1M KCl and
subjected to subcellular fractionation by ultracentrifugation, CDS
activity in the microsomal fraction (MF) was no longer different
in the control as compared to the treated tumors (white bars
in Figures 7C,D). As expected, the addition of recombinant
Fra-1 (dark gray bars in Figure 7C) or c-Fos (dark gray bars in
Figure 7D) activated CDS but if in addition to the recombinant
Fra-1 or c-Fos proteins, the N-terminus deletion mutants were
included in the reaction, CDS activity decreased to similar levels
of those obtained in the MF treated with KCl 1M of each
condition (black bars in Figures 7C,D).
DISCUSSION
Most studies regarding c-Fos and Fra-1 are related to their role
as transcription factors. However, both proteins also activate
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FIGURE 6 | Fra-1-NA plus c-Fos-NA treatment decreases PCNA protein levels. Protein extracts prepared from the tumors excised from tumor-bearing Balb/c mice
treated or not with Fra-1-NA plus c-Fos-NA were subjected to western blot analysis to examine PCNA and α-tubulin (as loading control) levels as described under
Materials and Methods. PCNA and α-tubulin levels of all the tumors of the high dose treatment experiment with their controls are shown. Scatter dot plot represents
the densitometric quantification and horizontal bars the mean ± SEM (Student t-test). **p < 0.01. Control group: n = 4; treated group: n = 6.
phospholipid synthesis by a non-genomic mechanism (35). In
breast tumor models, c-Fos and Fra-1 activate phospholipid
synthesis and both do so through a mechanism that is
independent of their genomic activity (20). We previously
showed for c-Fos that its NA is implicated in the physical
association with the enzymes it activates whereas its BD is
essential for activation to occur (21, 26). Herein, we demonstrate
that in order to activate phospholipid synthesis in an invasive
triple negative breast tumor cell model, the MDA-MB231 cell
line, Fra-1, and c-Fos physically associate with CDS1 and enhance
total CDS activity. By contrast, neither protein associates with
or activates PIS. Both proteins associate with the enzyme they
activate through their NA domain and activate it through their
BD domain. Furthermore, in the presence of both NA deletion
mutants, colocalization of full-length Fra-1 and c-Fos with the
ER marker calreticulin decreases.
Of all the Fos family members, Fra-1 and c-Fos share the
highest homology, especially on their basic domains: key for
lipid synthesis activation (20). Although homology between
their N-terminus domains reaches only a 34%, the in silico
predicted disorder shows high order correlation in the central
region of these peptides (Supplementary Figure 3), suggesting
that these ordered regions are relevant for the oncoprotein-
enzyme interaction.
We hypothesized that the NA domains of Fra-1 and c-Fos
act as negative dominants that physically associate with enzymes
involved in the phospholipid synthesis pathway but without
activating them. Consequently, no proliferation can be expected
if activation of membrane biogenesis is impaired. Indeed,
the overexpression of Fra-1-NA, c-Fos-NA or both together,
significantly impairs MDA-MB231 and 4T1 cell proliferation
in comparison with control cells or cells transfected with the
empty vector pTQ2. Other authors and our previous reports
have shown that the silencing of only Fra-1 or c-Fos does
not significantly affect MDA-MB231 cell proliferation (18, 20).
However, silencing both proteins with siRNA or blocking their
cytoplasmic activities using specific antibodies, inhibits MDA-
MB231 cell proliferation (20). We inhibit tumor cell proliferation
by decreasing or blocking the cytoplasmic function of Fra-
1 and c-Fos without affecting their nuclear function as AP-1
transcription factors because both deletion mutants examined,
lack the AP-1 dimer formation domain (LZ) of the C-terminus
of these proteins and the recognition domain for their nuclear
translocator system (BD) (36, 37).
Fra-1 and c-Fos are overexpressed in breast tumor tissues
as compared with their undetectable levels found in normal
cells (20) with a direct relationship reported for the cytoplasmic
expression of Fra-1 and malignancy in breast tumor (38).
Furthermore, Fra-1 mRNA is overexpressed in triple-negative
breast tumors, compared to breast tumors positive for estrogen
or progesterone receptors (39). Fra-1 and c-Fos overexpression
together with PCNA immunoreaction are clearly observed in
tumor samples, whereas PCNA immunoreactivity and c-Fos and
Fra-1 expression levels are almost undetectable in the non-
pathological counterparts (20). Herein, the inhibitory effect on
proliferation of both NA deletion mutants were evident both
in vitro and in vivo in the 4T1 breast tumor model. After
the intratumoral delivery of liposomes containing Fra-1-NA
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FIGURE 7 | When grown in the same animal, Fra-1-NA+c-Fos-NA treatment impairs tumor growth and CDS activity. Mice bearing two tumors received intratumoral
injections of liposomes containing equal concentrations of Fra1-NA plus c-Fos-NA into one tumor and empty liposomes into the other. Peptide administered: 5
injections containing a total of 9 nmol of Fra-1-NA plus c-Fos-NA peptides per injection (dashed line) or vehicle (continuous line) delivered three times a week for 15
days. (A) Tumor volumes were measured at 3-day intervals during the treatment period. Results are expressed as the percent volume taking the volume of the tumor
at 10 days of inoculation as 100%. ***p < 0.001 (Two-way ANOVA, Bonferroni post-test) (B) Tumor growth rates were calculated for each group at the end of the
treatment as the slope of the curve obtained by plotting the log10 of the tumor volume in function of the days of treatment. Horizontal bars represent mean values.
***p < 0.001 (Paired t-test). Mice examined: n = 11. (C,D) CDS activity was measured in TH (light gray bars) and the microsomal fraction (MF) stripped with KCl 1M
(white, dark gray and black bars) from vehicle-treated tumors and Fra-1-NA plus c-Fos-NA-treated tumors of two mice. Recombinant wild type Fra-1 (C), recombinant
wild type c-Fos (D) and/or Fra-1-NA + c-Fos-NA (C,D) were added to the reaction as indicated in the figure. Experiments were performed in triplicate; bar graphs
represent the mean ± SEM. All experimental situations were compared to TH from the non-treated samples. *p < 0.05 (One-way ANOVA, Dunnett post-test).
plus c-Fos-NA, a significant decrease in tumor size and tumor
growth rate was observed. This response seems to be due to a
direct effect of the peptides rather than to a stress or systemic
effect on the animal since when two tumors were induced in
a single mouse, the one treated with Fra-1-NA plus c-Fos-NA
showed a decrease in tumor volume, tumor growth rate and
CDS activity as compared to its own control treated with empty
liposomes in the same mouse. In addition, PCNA protein levels
in the excised tumors from the treated group showed lower
expression levels than the control, evidencing that treated tumors
are less proliferative. Two different doses were tested in these
experiments, and, although in both cases a decrease in tumor
growth rate was observed, the highest concentration was more
effective. It should be mentioned that the doses assayed were
empirically determined since, although previous data on cancer
treatment with proteins is available, mostly antibodies [reviewed
in Scott et al. (40)], no previous reports were found using the
peptides evaluated herein.
These results highlight the potential use of Fra-1-NA
and c-Fos-NA as a new therapeutic strategy. Other authors
demonstrated that Fra-1 plays a key role in mediating the
transition to and in maintaining the population of breast cancer
stem cells and also observed from a compendium of clinical data
sets, that high Fra-1 mRNA expression correlates with a poor,
metastasis-free survival (18). In this context, further studies are
necessary to evaluate if the N-terminal deletion mutants are also
capable of inhibiting the proliferation of breast cancer stem cells.
The therapy proposed in this manuscript using c-Fos plus
Fra-1 deletion mutants has some advantages. First, Fra-1 and
c-Fos overexpression in breast tumor tissues in comparison
with undetectable levels in normal tissue confers per se high
tumorigenic tissue specificity because the deletion mutants
will interfere only with the activity of these proteins in
cells overexpressing their full-length versions. Moreover, these
peptides should not interfere with the canonical function of the
AP-1 transcription factors in normal cells since they do not
contain the domain required for AP-1 dimerization of full-length
c-Fos and Fra-1. The therapeutic use of peptides and proteins
is recognized as being highly selective for their in vivo targets
resulting in exceptionally high potencies of action and, at the
same time, relatively safe and well-tolerated with few off-target
effects (41, 42).
Frontiers in Oncology | www.frontiersin.org 10 June 2019 | Volume 9 | Article 544
Racca et al. Fra-1/c-Fos: Breast Cancer Therapy Targets
The application of these mutants as an adjuvant therapeutic
strategy to treat malignant breast tumors is promising and, since
other tumors such as brain, lung, liver, cervical, bladder also show
over expression of one or both of these proteins, it is expected
that this future therapeutic strategy will be readapted or slightly
modified to inhibit the growth and progression of all tumors
overexpressing Fra-1 and/or c-Fos.
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